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Abstract
Vascular endothelial growth factor C (VEGF-C) plays a critical role in tumor lymphangiogenesis and lymph node
metastasis. We report here that VEGF-C expression is regulated bymicroenvironmental stress including hyperthermia
and oxidative stress. Furthermore, we show that this stress response is mediated by transcriptional activation medi-
ated by lens epithelium–derived growth factor (LEDGF/p75). Ectopic expression of LEDGF/p75 in C6 rat glioma and in
H1299 human non–small cell lung carcinoma induced VEGF-C expression in vitro, whereas in subcutaneous mouse
tumor xenografts, LEDGF/p75 stimulated VEGF-C expression and augmented angiogenesis and lymphangiogenesis.
Conversely, overexpression of a LEDGF/p75 native antisense or LEDGF/p75–targeted short interfering RNA down-
modulated VEGF-C expression. LEDGF seemed to conferred this activity on binding to a conserved stress response
element (STRE) located in the VEGF-C gene because mutating the STRE was sufficient for the suppression of basal
and stress-induced activations of the VEGF-C promoter. Thus, the study reported here identified a role for LEDGF/p75
in stress-regulated transcriptional control of VEGF-C expression. These results provide a possible link for LEDGF/p75 in
tumor lymphangiogenesis and cancer metastasis. Hence, our data suggest the LEDGF–VEGF-C axis as a putative bio-
marker for the detectionof stress-induced lymphangiogenesis andLEDGFas apotential target for antimetastatic therapy.
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Introduction
Blood and lymphatic vessels provide complementary functions in the
maintenance of tissue homeostasis. Blood circulation is optimally de-
signed for efficient delivery and clearance of low–molecular weight
nutrients and waste products, as well as the rapid systemic exposure
of all tissues to circulating erythrocytes, immune cells, and hormones.
The lymphatic system, however, provides a unidirectional route for the
clearance of extravasated interstitial fluid, macromolecules, and im-
mune cells from the tissues to the blood circulation through the drain-
ing lymph nodes. Both vascular systems were implicated in providing
routes for tumor escape and metastatic dissemination.
Development and maintenance of the blood and lymphatic vascular
systems are coupled through multiply shared receptors expressed on
both lymphatic and blood endothelial cells. Accordingly, angiogenesis
and lymphangiogenesis are tightly coregulated, mainly by vascular
endothelial growth factors A and C (VEGF-A and -C), two members
of the VEGF family. Both VEGF-A and -C induce endothelial cell sur-
vival, proliferation, migration, and induction of permeability. VEGF-A
predominantly mediates its activity through activation of VEGF re-
ceptors 1 and 2 (VEGFR-1 and -2) but not VEGFR-3. VEGF-C is
produced as a precursor and undergoes stepwise proteolytic process-
ing, generating 31/29- and 21-kDa fragments with varying affinities
for the various VEGF receptors. The mature form of VEGF-C activates
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VEGFR-2 on blood endothelial cells. This induces a response similar to
that induced by VEGF-A, including increased vascular permeability,
proliferation, and migration of vascular endothelial cells but with less
potency than VEGF-A [1,2]. VEGF-C, in addition to its angiogenic
properties, is a potent inducer of lymphangiogenesis. Binding of the
31/29-kDa protein to VEGFR-3 on lymphatic endothelial cells induces
lymphangiogenesis in development, cancer, and wound healing [3,4].
The role of VEGF-C in peritumor lymphatic remodeling and lymph
node metastatic spread was demonstrated in a variety of human cancers,
including thyroid, prostate, gastric, colorectal, and lung [5,6]. In addi-
tion, ectopic stable expression of VEGF-C in cancer cell lines as well as
in various mouse tumor models promoted tumor lymphangiogene-
sis and resulted in an increased incidence of lymph node metastasis
[7–9]. In addition to its role in lymphangiogenesis, VEGF-C is secreted
in inflammation by cells belonging to the inflammatory progeny [10].
Mice deficient in VEGF-C lack cell sprouting from the cardinal vein
and exhibit impaired formation of lymph sacs and edema [3]. Silencing
of VEGF-C expression, either by using short hairpin RNA or by apply-
ing soluble VEGFR-3, has been shown to inhibit VEGF-C–induced
tumor lymphangiogenesis metastasis and enhance survival [11–13].
Maintenance of tissue homeostasis should include mechanism that
would augment the functional and structural capacity of the lym-
phatic bed in response to short- and long-term increased need for lym-
phatic clearance. Thus, an immediate rise in tissue interstitial pressure
pulls the anchoring filaments on the lymphatic endothelial cells, leading
to increased permeability and uptake of fluids [14]. We have recently
demonstrated, by magnetic resonance imaging, the induction of inter-
stitial convection and lymphatic drain, in response to overexpression of
VEGF-A [15–17]. Moreover, VEGF-C expression was demonstrated
to be induced by interstitial convection and edema in a number of
experimental models [18–20] and in response to inflammation and
proinflammatory factors, including tumor necrosis factor α and inter-
leukin 1β [21–23]. Accordingly, various environmental stress signals
have been implicated in the induction of VEGF-C expression [24–26].
Recently, it was demonstrated that heparanase induces VEGF-C ex-
pression and facilitates tumor xenograft lymphangiogenesis [27].
The aim of this study was to evaluate the molecular basis for regu-
lation of VEGF-C expression by microenvironmental stress signals. A
recent study reported that expression of VEGF-C can be induced by
the osmosensitive transcription enhancer TonEBP [28]. In the study
reported, we present a novel molecular machinery, controlling lymph-
angiogenesis through the activation of VEGF-C expression. We show
here that oxidative stress and hyperthermia augmented VEGF-C ex-
pression in the lung tumor H1299 cells. Activation of VEGF-C tran-
scription is conferred by the stress response element (STRE) located
in the promoter of VEGF-C through the activity of the transcription
factor lens epithelium–derived growth factor (LEDGF)/p75.
LEDGF (designated also as PSIP1 and DFS70 autoantigen) was
identified as a survival factor that enhances growth and resistance to cell
death induced by oxidative stress, hyperthermia, and serum deprivation
[29,30]. LEDGF/p75 was recently implied as a key player in tumor
progression and maintenance both in mouse tumor models and in var-
ious human cancers [31]. LEDGF was implicated in multiple pathways
affecting cancer progression and thus predicts poor survival [32,33]. In
addition, it has emerged as an important cellular cofactor involved in
tethering of human immunodeficiency virus 1 integrase to chromatin,
protecting it from degradation [34]. Indeed, LEDGF is predominately
localized to the nucleoplasm of most cell types and is associated with the
chromosomes [29]. LEDGF/p75 was reported to bind two different
consensus core sequences, namely, heat shock element (HSE) and
STRE [35]. However, other studies reported that LEDGF tethers
JPO2, a MYC binding protein, to chromatin, affecting transcription
in an STRE-independent manner [36,37].
In the study reported here, we demonstrate the role of LEDGF/P75 in
inducing tumor VEGF-C expression in response to hyperthermia and oxi-
dative stress. Moreover, human non–small cell lung carcinoma (H1299)
and rat glioma (C6) cells with a low basal expression of LEDGF/p75
and VEGF-C were induced to overexpress LEDGF/p75, resulting in an
increased production of biologically active VEGF-C and corresponding
induction of subcutaneous angiogenesis and lymphangiogenesis.
Materials and Methods
Cell Cultures and Reagents
Cells were cultured in minimum essential medium (human lung
cancer A549 cells [ATCC, Manassas, VA] and C6 rat glioma cells
[ATCC]), Dulbecco’s modified Eagle medium (transformed African
green monkey fibroblast cells COS7 [ATCC]), or RPMI (human non–
small cell lung carcinoma, H1299 [ATCC]) medium supplemented with
10% fetal bovine serum, penicillin, and streptomycin. All cells were
maintained in 5% CO2/95% air at 37°C.
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from cells using Tri Reagent (Molecular
Research Center, Cincinnati, OH). Two micrograms of total RNA
was used for first-strand DNA synthesis using SuperScript II RNase
H-reverse (Invitrogen, Carlsbad, CA). Polymerase chain reaction (PCR)
was performed with the following forward and reverse primers: human
VEGF-C (accession no. NM005429: 5′-CTGCTCGCCGCTGCG-
CTG and 5′-GTGCTGGTGTTCATGCACTGCAG), human
LEDGF/p75 (accession no. AFO63020: 5′-CACACAGAGATGATT-
ACTACACTG and 5′-CCATCTTGAGCATCAGATCCTC), mouse,
and the native antisense rat LEDGFas (accession nos. AK042735 and
CB576984: 5′-CCTGTTGGTTCCTTCTCTAGCand 5′-GGCGGT
TCAAAGTCAGTCAAG), human LEDGFas (accession no.
AV716383: 5′-CCTGTTTG TTCCTTCTCTAGC and 5′-
GGCGATTCAAAGTTAGTC AGG), and human GAPDH (accession
no. BC004109: 5′-CGGAGTCAACGGATTTGGTCGTAT and 5′-
AGCCTTCTCCATGGTGGTGAAGAC). All PCR conditions and
primers were optimized to produce a single product of the correct base
pair size in the linear range of the reaction. The target messenger RNA
(mRNA) expression level was calculated as the ratio of the target mRNA
to GAPDH mRNA for each sample.
Expression Vectors and Stable Transfections
LEDGF and LEDGF antisense (LEDGFas) sequences were reverse-
transcribed from H1299 mRNA and PCR-amplified using Phusion
high-fidelity DNA polymerase (Finnzymes, Espoo, Finland) together
with the following forward and reverse primers: LEDGF, 5′-ATGACT-
CGCG ATTTCAAACCTGG and 5′-CTAGTTATCTAGGGTAGA-
CTCCTTCAG; LEDGFas, 5′-CCTGTTTGTTCCTTCTCTAGC
and 5′-GGCGATTCAAAGTTAGTCAGG.The fragments were ligated
into pCR-BluntII-TOPO (Invitrogen), and their sequence fidelity was
confirmed by DNA sequence analysis. Inserts were restricted and li-
gated into pIRES expression vector containing the human EF-1a pro-
moter [38]. Stable transfections were carried out with Lipofectamine
2000 reagent (Invitrogen), and 48 hours after transfection, puromycin
(2.5 mg/ml; Sigma, St. Louis, MO) was added to initiate selection. An
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average of 50 puromycin-resistant clones was pooled and analyzed for
both luciferase activity and LEDGF expression.
Luciferase Reporter Assays
VEGF-C promoter sequence (GenBank accession no. NM-005429)
was amplified from human genomic DNA by PCR, using forward (5′-
CCGCCGCAGCGCCCGCG) and reverse (5′-GAGAAGAAGCC-
CAGCAAGTG) primers containing BamHI and XhoI restriction sites,
respectively. To construct the pVEGF-Cwt-Luc, the product was
digested and ligated into pLuc plasmid, which encodes firefly luciferase.
The fidelity of the insert was confirmed by DNA sequence analysis.
Two mutated pVEGF-C reporter vectors were generated: mutations
were introduced into the STRE sequence located within the VEGF-C
gene using mutated PCR primers (pVEGF-Cm1-Luc, 5′-CACTTC-
GGGGAAGAAAAGGGAGGAGGGGG; and pVEGF-Cm2-Luc,
5′-GCCAGAGCCCTCGTTTTTCTCCTTTCTTTTCTTCCCCG
AAGTG AGAG). For transfections, cells (105 per well) were plated in a
24-well plate and transfected 24 hours later with pSV-Renilla (40 ng),
luciferase reporter (300 ng), and 500 ng of pIRES alone, pIRES encod-
ing LEDGF/p75 or pIRES encoding LEDGFas, using Lipofectamine
2000 reagent (Invitrogen). Twenty-four hours after transfection, lucifer-
ase assay was performed using the dual-luciferase reporter assay system
(Promega, Madison, WI). Firefly luciferase activity was normalized to
Renilla luciferase activity for each transfected well. For down-modulation
analysis of LEDGF/p75 activity, H1299 cells stably expressing pVEGF-
Cwt-Luc construct were transfected either with a specific synthetic short
interfering RNA (siRNA) targeting nucleotide 1342 to 1361 (5′-AGA
CAG CAU GAG GAA GCG dTdT; Dharmacon, Lafayette, CO)
[39] or with a nontarget control siRNA (Dharmacon). Forty-eight
hours later, cells were stimulated as indicated.
Chromatin Immunoprecipitation Assays
H1299 control cells, or stimulated as indicated, were fixed in 1%
formaldehyde for 10 minutes and subjected to chromatin immuno-
precipitation (ChIP) assay using the EZ ChIP Chromatin Immuno-
precipitation Kit (Upstate Biotechnology, Lake Placid, FL) with
anti-LEDGF antibodies (C16; Santa Cruz, Santa Cruz, CA). PCR
was performed using primers to amplify the VEGF-C promoter (for
details, see Luciferase Reporter Assays section). Total genomic DNA
amounts were evaluated using GAPDH primers.
Immunoblot Assays
Whole-cell lysates were prepared in ice-cold RIPA buffer (20 mM
Tris, pH 7.4, 137 mM NaCl, 10% glycerol, 0.5% [wt/vol] sodium
deoxycholate, 0.1% [wt/vol] sodium dodecyl sulfate (SDS), 1% Triton
X-100, 2 mM EDTA) containing 1 mM phenylmethylsulfonyl fluo-
ride and protease inhibitor cocktail (Sigma) and fractionated by
SDS–polyacrylamide gel electrophoresis. Primary antibodies against
the following proteins were used: VEGF-C (C-20; Santa Cruz),
LEDGF/p75 (C16; Santa Cruz), and β-tubulin (Santa Cruz). HRP-
conjugated antirabbit secondary antibodies ( Jackson ImmunoResearch
Laboratories, West Grove, PA) were applied.
In Vivo Imaging of Tumor Models
Two different tumor models were used to study blood and lymphatic
vasculature. At the end point of the experiment, tumors were fixed (over-
night; 4% paraformaldehyde in diethylpyrocarbonate–PBS) and then
embedded in paraffin blocks. All the animal experiments were approved
by the Weizmann Institutional Animal Care and Use Committee.
In vivo imaging of tumors in dorsal skinfold window chamber
model. Window chambers were implanted into the dorsal skinfold
of 8-week-old CD-1 nude female mice [40–42]. Briefly, a dorsal skin
flap was created and fixed using two metal frames (Research Instru-
ments, Inc, Durham, NC). On one side, a 12-mm circular piece of
skin was removed and replaced by a glass cover to enable visual access.
Tumors were initiated 48 hours after surgery by injection of 2 × 106 (in
30 μl of PBS) of H1299-DsRed2-IRES (control) or H1299-DsRed2-
LEDGF cells to the center of the chamber. Tumor vascular morphology
was imaged 4 and 8 days after injection, using the dynamic light
scattering imaging (DLSI), which enables imaging of functional blood
microvessels using intrinsic signal produced by flow of red blood cells
[43,44]. Tumors expressing DsRed were detected by fluorescence
microscopy. The imaging setup was composed of a fluorescent zoom
stereo microscope SZX12 (Olympus, Japan) coupled with a CCD
camera PIXELFLY QE, 12 bit (PCO, Germany), and a laser illumina-
tion unit for DLSI (ELFI-C; Elfi-Tech Ltd, Israel).
In vivo imaging of subcutaneous tumors in the mouse ear.
Tumors were initiated by intradermal inoculation of C6-DsRed2-IRES
(control) or C6-DsRed2-LEDGF (3 × 105 cells in 5 μl of PBS) to the
ear of 8-week-old CD-1 nude female mice. Seven days later, high–
molecular weight dextran–fluorescein isothiocyanate (FITC, 500 kDa;
Sigma) was injected into the ear to enable lymphatic vasculature visuali-
zation, using a fluorescent zoom stereomicroscope (see section 1). Three
channels were collected for each tumor: green fluorescence (dextran-
FITC), red fluorescence (tumor DsRed), and DLSI (subjected during
processing) for the blood vessels [43,44].
Image Processing and Fractal Analysis
In vivo acquired images were processed using ImageJ (National Insti-
tutes of Health; http://rsb.info.nih.gov/ij/ ). Blood vessels imaged using
the DLSI method in the chamber model were traced using “NeuronJ”
plug-in (Written by Erik Meijering), producing an image mask.
“Parlance” algorithm images were subjected to fractal analysis to
derive the vasculature complexity [45,46]. Briefly, the algorithm covers
the image using a set of different-sized boxes. The number of boxes of
each size was counted, and its log was plotted against the log of the
box length. The positive value of the regression line slope Df = −S
was derived, representing the Fractal dimension, which is a quantitative
geometric parameter indicative of the complexity (branching and den-
sity) of the vascular network. Angiogenesis and lymphangiogenesis
would result in higher Df values representing higher complexity of
the vascular network.Dfwas reported to provide an objective parameter
for quantification of expansion of the vascular network in a variety of
angiogenesis assays [47–51].
Histologic Analysis
Fixed paraffin-embedded tumor blocks were sectioned serially.
The first slide was stained with hematoxylin and eosin, whereas other
representative slides underwent immunohistochemical staining and
in situ hybridization. The immunohistochemical staining sections
were deparaffinized with xylene for 5 minutes, followed by sequential
ethanol hydration and double-distilled water. Sections were then
washed with PBS for 5 minutes and blocked by overnight incuba-
tion with 1% BSA in PBS at 4°C. To visualize blood and lymphatic
endothelial cells, sections were stained with anti-CD34 (Cedarlane
Laboratories, Burlington, NC) or LYVE-1 (Fitzgerald Industries Inter-
national, Concord, MA) antibodies, respectively.
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In Situ Hybridization
A specific probe for the VEGF-C coding region was prepared by
reverse transcription–polymerase chain reaction (RT-PCR) using
forward (5′-CTGTGTCCAGCGTAGATGAGC) and reverse (5′-
GTAGACGGACACAC ATGGAGG) primers. This probe shares a
high degree of homology with both human and mouse complemen-
tary DNA (accession nos. NM005429 and NM009506, respectively).
Sequence was verified, and the fragment (282 bp) was cloned into the
pGEM-T Easy vector system (Promega). Digoxigenin-labeled ribo-
probes were produced by in vitro transcription using a digoxigenin
RNA labeling kit (Roche, Basel, Switzerland). Paraffin sections were
deparaffinized, and then proteinase K (Sigma) digestion was carried
out followed by postfixation in 4% paraformaldehyde in PBS. After
two TBS rinses, the sections were dehydrated and air-dried. Slides were
then preincubated with hybridization mixture (2× SSC, 10% dextran
sulfate, Denhardt solution (Sigma), 50% formamide, and 0.02% SDS)
in a humidified oven for 30 minutes at 65°C. Hybridization with the
VEGF-C probe was initialized by the addition of digoxigenin-labeled
antisense or sense riboprobes (1 μg/ml), as well as yeast transfer RNA
(100 mg/ml; Sigma). The hybridization procedure was carried out over-
night at the previously mentioned conditions. After incubation, slides
were rinsed (2 × 10 minutes at room temperature) in 2× SSC containing
EDTA (1 mM), once (1 hour, 50°C) in 0.2× SSC containing EDTA,
twice (10 minutes at room temperature) in 0.5 × SSC, TBS for (5 min-
utes at room temperature), and TBS containing BSA (1%; Sigma) for
1 hour at room temperature. The slides were then incubated with anti-
digoxigenin alkaline phosphatase (Roche) and were developed using
a 5-bromo-4-chloro-3-indolyl-phosphate–nitro blue tetrazolium sub-
strate kit for histochemistry (Roche).
Bioinformatics Analysis
Transcription factor binding site prediction was performed with
TFSearch Version 1.3 (http://www.cbrc.jp/research/db/TFSEARCH.
html). Genomic analyses were performed at the University of California
Santa Cruz (UCSC) genome browser: http://genome.ucsc.edu. The
genome builds used were as follows: mouse – mm8; human – hg18;
rat – rn4; cow – BosTau2. Tracks used (from the various genomes) in-
clude mRNA; Spliced ESTs; ESTs; Human, Mouse, Cow, and Rat
Nets; and Conservation.
Statistical Analysis
Data are presented as mean ± SD of at least three independent experi-
ments. Statistical significance (P < .05) was assessed by t test.
Results
LEDGF/p75 Interacts with VEGF-C
Using in silico analysis, five potential LEDGF/p75 binding sites
(STRE) were identified in the promoter region of the human VEGF-C
(chr4:177,950,457–177,950,924, UCSC build hg18; Figure 1A,
underline), two of which were found to be highly conserved between
various mammalian species (Figure 1B). This finding suggests that
LEDGF can potentially bind the VEGF-C promoter and adjust its
expression in response to microenvironmental stress. To confirm that
LEDGF/p75 binds to these sequences within living cells, a ChIP assay
was performed. Indeed, using a specific antibody, LEDGF/p75 was
found to bind the VEGF-C promoter region, whereas no binding
was detected for nonspecific antibodies (Figure 1C ).
To further test the possible relationship between the LEDGF tran-
scriptional coactivator and the VEGF-C gene, we evaluated its effect
in human non–small cell lung carcinoma (H1299) cells that have low
endogenous expression of VEGF-C. Thus, LEDGF/p75 was over-
expressed in the human non–small cell lung carcinoma H1299 cell
line, and the levels of VEGF-C mRNA were examined. Transfection
was carried out using either an empty expression vector (pIRES) as a
control or a construct encoding the rat LEDGF gene, tagged with the
human influenza virus hemagglutinin (HA) epitope (pIRES-LEDGF).
Several puromycin-resistant pools of cells (50 individual clones/pool)
along with individual clones were selected, and the expression level of
LEDGF/p75 was evaluated by Western blot analysis using anti-HA
antibodies (Figure 1D). The mRNA levels of LEDGF/p75, VEGF-A,
and VEGF-C were examined by RT-PCR in the same pools and clones
of cells (Figure 1, E and F). A notable correlation between the LEDGF/
p75 and VEGF-C mRNA levels was detected both in the pool of cells
and in the individual clones (regression analysis for all cell lines,P = .007;
Figure 1,D–F). No such correlation was observed between the mRNA
levels of VEGF-A and either VEGF-C or LEDGF/p75 (regression
analysis of all cell lines, P = .35 and .7, respectively; Figure 1, D–F).
LEDGF Induces VEGF-C Promoter Activity in a
STRE-Dependent Manner
We further investigated the ability of LEDGF/p75 to induce VEGF-C
transcription by activation of its promoter; the 468-bp DNA fragment
spanning the putative STREs found in the VEGF-C promoter region
(Figure 1A) was isolated and inserted into a promoter-less luciferase
plasmid. In this way, a pVEGF-C-Luc reporter was constructed, enabling
detection of the VEGF-C promoter activity. Two additional cell lines
with low endogenous expression of VEGF-C, rat glioma C6, and
COS7 cells were transiently cotransfected with the pVEGF-C-Luc plas-
mid together with either a LEDGF/p75–encoding construct (pIRES-
LEDGF) or an empty vector (pIRES). Analysis of cell lysates revealed
a three-fold induction of the VEGF-C promoter activity in cells express-
ing LEDGF/p75 compared with control (Figure 2, A and B). Stable
transfection of C6 and H1299 cells with the same constructs resulted
in similar results (Figure 2, C and D).
To determine the importance of the two conserved putative STREs
found in the VEGF-C promoter region, several G-to-A substitutions
were introduced into these sites (Figure 2E ). The 468-bp promoter
sequence of VEGF-C, bearing the indicated mutations, was then in-
serted into a promoter-less luciferase plasmid. In the pVEGF-Cm1
plasmid, the function of the proximal putative STRE was disrupted
by three mutations. In the pVEGF-Cm2 plasmid, the function of
both STREs, as well as one AGG box, was disrupted by nine muta-
tions (Figure 2E). H1299 cells were transiently cotransfected with the
mutated constructs, together with either a LEDGF/p75–encoding con-
struct (pIRES-LEDGF) or an empty vector (pIRES). Cell lysate analy-
sis indicated that the point mutations introduced within the proximal
putative LEDGF/p75 binding site (pVEGF-Cm1-Luc) resulted in a
modest 15% loss of the promoter activity compared with the intact pro-
moter construct (pVEGF-Cwt-Luc; Figure 3F ). However, disruption
of both the proximal and the distal STREs (pVEGF-Cm2-Luc) caused
a 45% and 68% loss of promoter activity compared with the control
either in the absence or in the presence of LEDGF/p75 overexpression,
respectively (Figure 2F ). These data suggest that LEDGF/p75 selec-
tively induces VEGF-C transcription through binding to this conserved
STRE sequence found in the promoter region.
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LEDGF/p75–Induced Expression of VEGF-C Is Activated
by Environmental Stress Signals
Previous studies reported that activation of LEDGF/p75 expres-
sion by microenvironmental stress results in induced expression of
LEDGF/p75 target genes [25,52,53]. Thus, the role of LEDGF/p75
in the regulation of VEGF-C mRNA expression by oxidative stress
(0.2 μM H2O2), or thermal stress (42°C), was evaluated in H1299
human lung cancer cells (Figure 3). VEGF-C and LEDGF mRNA
and protein levels were coinduced under oxidative stress conditions
as early as 1 hour; they reached up to 3- and 1.5-fold induction, res-
pectively, after 6 hours of stimulation as determined by RT-PCR (Fig-
ure 3, A and B) and immunoblot using a subunit-specific antibody
Figure 1. The VEGF-C gene contains putative LEDGF/p75 binding sites. (A) Nucleotide sequence of the 468-bp 5′-flanking region of human
VEGF-C gene. The nucleotide sequences are numbered in relation to the ATG, which is designated “+1”. Underlining indicates an STRE, the
putative LEDGF binding site. (B) Conservation among species of a putative binding unit for LEDGF was identified using the conservation
track of the UCSC genome browser, and the positions of mismatches are indicated. The binding site runs from −426 to −407 (human
chr4:177,950,885–177,950,866). (C) ChIP assays were performed using specific primers for the 468-bp VEGF-C promoter (A) and nonspe-
cific antibodies (ns) or anti–LEDGF/p75 antibodies to demonstrate specific binding of LEDGF/p75 in H1299 cells. Evaluation of total genomic
DNAwas carried out with GAPDH primers. (D) H1299 human lung cancer cells stably transfected either with a control pIRES vector or with a
construct encoding rat LEDGF tagged with an influenza virus hemagglutinin epitope (pIRES-HA-LEDGF). Puromycin-resistant pools of cells
and individual clones were selected from each of the lines. Immunoblot assay of LEDGF expression levels of puromycin-resistant stably
transfected pools (lanes 1 and 2) and individual clones (clones 3-7) using anti–HA antibodies. Protein amounts were quantified using anti–β-
tubulin antibodies. (E) RT-PCR analysis of the expression of human VEGF-C, VEGF-A, GAPDH, and transfected rat LEDGF genes was carried
out on total RNA extracted from the previously mentioned stably transfected pools and individual clones. (F) Relative densities of the
scanned bands normalized against GAPDH.
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directed to the precursor of the human VEGF-C or the p75 variant of
LEDGF (Figure 3C ).
The role of LEDGF/p75 binding sites in the VEGF-C promoter
for oxidative and thermal-induced promoter activity was determined
by the luciferase assay. H1299 human lung cancer cells were transiently
transfected either with intact (pVEGF-Cwt-Luc) or with each one of
the two mutated constructs (pVEGF-Cm1-Luc and pVEGF-Cm2-
Luc). Subsequently, luciferase activity was measured in cell extracts of
H1299 human lung cancer cells subjected to oxidative stress (0.2 μM
H2O2 for 24 hours). A 10-fold increase of pVEGF-C intact reporter
(pVEGF-Cwt-Luc) activity was detected after oxidative stress exposure
compared with unstimulated cells (Figure 3D). Disruption of the prox-
imal STRE site in pVEGF-Cm1-Luc diminished the promoter activity
by 23%, whereas inactivation of both LEDGF/p75 sites in pVEGF-
Cm2-Luc abolished 76% of the overall activity (Figure 3D). These re-
sults were corroborated by ChIP analysis, which demonstrated that the
binding of LEDGF/p75 to the VEGF-C promoter was significantly en-
hanced as early as 1 hour after exposure to oxidative stress (Figure 3E).
A similar regulation of VEGF-C expression by LEDGF/p75 mRNA
was found for thermal stimulation. Thermal stress (42°C for 6 hours)
resulted in a two-fold enhancement in VEGF-C mRNA (Figure 3,
F and G) and protein (Figure 3H ) levels. In addition, thermal stress
elicited a two-fold increase in VEGF-C promoter activity, which was
reduced by 23% and 73% on disruption of just the proximal (m1)
or both proximal and distal (m2) STREs, respectively (Figure 3I ). As
for oxidative stress, ChIP analysis demonstrated enhanced binding of
LEDGF/p75 to the VEGF-C promoter as early as 1 hour after exposure
to thermal stress (Figure 3J ).
As further evidence for the role of LEDGF/p75 in mediating stress-
induced expression of VEGF-C, both LEDGF/p75 and VEGF-C were
significantly induced when H1299 human lung cancer cell cultures
were subjected to elevated column of culture medium, resulting in
hypoxic condition and slightly elevated hydrostatic pressure (Fig-
ure W1). These results indicate that various stress signals enhance the
transcriptional activity of VEGF-C gene in a LEDGF/p75 (and STRE)–
dependent manner.
LEDGF cis-Native Antisense Transcript and siRNA
Diminish VEGF-C mRNA Expression
A search of the LEDGF/p75 locus in the mRNA track of the mouse
genome database (UCSC genome browser [54], genome build mm8;
Figure 4A) identified a few complementary DNA oriented in a direc-
tion consistent with their transcription from the opposite strand of the
LEDGF locus, representing putative cis-encoded natural antisense
mRNA of LEDGF. One of the putative cis-encoded natural antisense
transcripts (cis-NATs), AK042735, was specific to the p75 variant of
LEDGF. AK042735 is a 3184-bp-long single-exon transcript and does
not seem to encode for a protein. It overlaps exons 11 to 14 of LEDGF/
p75 on the opposite strand (Figure 4B) and is in complete overlap with
the LEDGF/p75 locus [55]. Additional database searches identified
similar EST clone sequences within the rat and cow EST databases
(genome builds rn4 and BosTau2, respectively; Figure 4C ). Further-
more, in the human database, two discontinuous ESTs were discovered
in silico (genome build hg18), which were found, by RT-PCR and
DNA sequence analyses, to be contiguous mRNA (Figure 4, C and D).
Similarly, the existence of mouse and rat putative cis-NATs was verified
Figure 2. LEDGF/p75 transcriptionally activates VEGF-C expression in an STRE-dependent manner. A luciferase reporter gene containing
the 5′-flanking region of human VEGF-C gene (Figure 1A, pVEGF-C-Luc) was transiently cotransfected with a control empty vector
(pIRES) or with a construct encoding LEDGF/p75 into rat glioma C6 or COS7 cells (A and B, respectively). Luciferase activity under each
experimental condition was scaled relative to the activity in control cells (mean ± SD, n = 3). (C and D; upper panel) Western blot
analysis carried out using anti–HA antibodies of protein extracted from C6 rat glioma (C) or human H1299 (D) cells stably expressing
the rat LEDGF protein tagged to hemagglutinin (HA) epitope (pIRES-LEDGF) after selection with puromycin. (C and D; lower panel) Mea-
surement of luciferase activity in C6 (C) or H2299 (D) cells stably expressing either LEDGF protein (pIRES-LEDGF) or the empty control
vector (pIRES) transiently transfected with the pVEGF-C-Luc construct. (E) Wild type (wt) and two mutated (m1 and m2) sequences of the
conserved LEDGF/p75 binding sites are presented, and the G-to-A substitutions are indicated in gray. (F) H1299 cells were transiently
cotransfected either with intact pVEGF-Cwt-Luc reporter or pVEGF-Cm1-Luc, pVEGF-Cm2-Luc together with LEDGF/p75 expression vector
or a control empty vector (+ and − indicate presence and absence of each construct; mean ± SD, n = 3).
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Figure 3. VEGF-C expression is induced by environmental stress. (A) VEGF-C and LEDGF-p75 mRNA expression was analyzed by RT-PCR
analysis in H1299 human lung cancer cells exposed for 1 and 6 hours to 0.2 mMH2O2 relative to untreated cells. (B) Relative intensity of the
bands normalized against GAPDH. (C) Immunoblot assay of VEGF-C, LEDGF, and β-tubulin in H1299 cells treated with 0.2 mMH2O2 for 6 or
12 hours or left untreated. (D) Luciferase reporter assay was used with a construct composed of a 468-bp VEGF-Cwild-type gene fragment
(pVEGF-Cwt-Luc) or mutation constructs carrying G-to-A substitutions in the LEDGF/p75 binding sites (pVEGF-Cm1-Luc and pVEGF-Cm2-
Luc). H1299 cells transfected with the previously mentioned reporters were stimulated 24 hours after transfection with 0.2 mM H2O2 or
were left untreated (mean± SD, n=3). (E) LEDGF binding to VEGF-C gene sequenceswas analyzed by ChIP. Chromatin from cells that were
exposed to 0.2 mMH2O2 for 1 and 4 hours or left untreated (0 hour) was immunoprecipitated (ChIP) with anti–LEDGF/p75–specific antibody
and analyzed by PCR using primers spanning the 468-bp VEGF-C promoter (Figure 1A). Evaluation of total genomic DNAwas carried out with
GAPDH primers. (F) VEGF-C and LEDGF/p75 mRNA expression was analyzed by RT-PCR analysis either in H1299 lung cancer cells grown at
42°C for 6 hours, transferred for an additional 6-hour incubation at 37°C (12 hours) or left at 37°C (0 hour). (G) Relative intensity of the bands
normalized to GAPDH. (H) Immunoblot assay of VEGF-C, LEDGF, and β-tubulin in H1299 cells treated as indicated in panel F. (I) Luciferase
reporter assay carried out with pVEGF-Cwt-Luc or two mutated constructs pVEGF-Cm1-Luc and pVEGF-Cm2-Luc. H1299 cells transfected
with the previously mentioned reporters were heat-activated (42°C) for 6 hours and then maintained for an additional 6 hours at 37°C
(+ and − indicate presence and absence of each construct, respectively; mean ± SD n = 3). (J) ChIP analysis as was described in
panel E, except that cells were heat-activated (42°C) for the indicated time.
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by RT-PCR (Figure 4D), and the fidelity of the products was con-
firmed by DNA sequence analysis.
To investigate the biologic activities of LEDGF/p75 cis-NATand its
significance with respect to the regulation of VEGF-C mRNA and pro-
tein levels, the human cis-NAT (LEDGFas) was inserted into the pIRES
plasmid vector (pIRES-LEDGFas) and used to transfect human lung
A549 cells to generate stable transfectants. A pool of clones was selected
by puromycin, and the expression level of LEDGFas was found to in-
crease by two-fold compared with cells transfected with an empty vector
(Figure 4, E and F ). The expression of LEDGFas reduced LEDGF/p75
sense mRNA by only 15% but strongly reduced VEGF-C mRNA lev-
els (46%; Figure 4, E and F ). Moreover, the expression of LEDGFas
resulted in a robust reduction in protein levels of both LEDGF/p75
and VEGF-C (Figure 4G).
The ability of LEDGFas to interfere with stress-induced transcrip-
tional activation of the VEGF-C promoter was tested in H1299 human
lung cancer cells transiently cotransfectedwith pVEGF-C-Luc construct
together with either a construct encoding the LEDGF/p75 antisense
transcript or an empty pIRES vector. Cells were subjected either to
oxidative (0.2 mM H2O2 for 24 hours) or thermal (42°C for 6 hours)
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stress. Both basal and stress-induced promoter activities were signifi-
cantly attenuated by the presence of LEDGFas expression (Figure 4,
H and I ).
The role of LEDGF/p75 in basal and stress-induced expressions of
VEGF-C were further highlighted by the ability to attenuate the base-
line expression of VEGF-C and substantially suppress stress-induced
expression of VEGF-C using siRNA targeting LEDGF/p75 (Figure 4J ).
H1299 cells showed a significant 21% attenuation of VEGF-C promoter
activity by knockdown of LEDGF/p75 expression relative to cells treated
with nontargeted siRNA or control cells (P < .05; 1-tailed t test). Robust
activation of VEGF-C promoter expression was observed by H2O2 and
hyperthermia in untreated cells as well as cells transfected with non-
specific siRNA (P < 2 × 10−6; 2-tailed t test). Knockdown of LEDGF/
p75 attenuated the activity of VEGF-C promoter by 60% for H2O2
and by 32% for hyperthermia (P < .001; 2-tailed t test; relative to control
cells and cells treated with nonspecific siRNA subjected to the respec-
tive stress).
These results confirm that LEDGF mediates VEGF-C activity and
that targeting its expression can be used to suppress VEGF-C in tumors.
Moreover, we showed here the activity of the LEDGF/p75 cis-NAT, sug-
gesting that it may have an important role in physiological regulation
of VEGF-C expression.
Figure 5. LEDGF-induced remodeling of blood and lymph vessels network. In vivo imaging of H1299 tumors developed in skinfold window
chamber (A–D, G). (A–D) Overlay of tumor fluorescence (red) and blood vessels processed using DLSI image (green). Tumors were initiated
in the CD-1 nudemice by injecting subcutaneously into a window chamber H1299 cells cotransfected with DsRed and either a control or an
LEDGF-encoding plasmid (C, D). Tumor development was followed and imaged 4 (B) and 8 (D) days after tumor cell inoculation. Graph (G)
indicates a mean fractal dimension value – D, calculated by fractal box count method [45], represents the complexity of the blood vessels’
network. Blood vessels’ network induced by the LEDGF-overexpressing tumors is significantly more complex (P = .025). In vivo imaging
of C6 tumors developed in the edge of mouse ear (E, F, and H). Overlay of tumor fluorescence (red), blood vessels’ DLSI image, and lymph
vessels network (green). Tumors were initiated in CD-1 nude mice by injection of C6 cells cotransfected with DsRed and either a control (E)
or an LEDGF-encoding plasmid (F). Tumor vasculature was imaged 7 days after cell inoculation. Complexity analysis of the lymphatic net-
work (H) shows the overexpression of LEDGF results in significantly (P = .0194) more complex network.
Figure 4. Attenuation of VEGF-C expression by cis-natural antisense RNA of LEDGF/p75 and by LEDGF/p75 siRNA. (A) Illustration of the
genomic structure of LEDGF variants. Black boxes indicate exons, and the connecting line indicates introns. The representative sequences
shown are AF339083 (LEDGF/p52) and NM_133948.4 (LEDGF/p75). (B) Diagram of the mouse cis-NATs. Accession numbers are as follows
(in order of start position from left to right): AK140469, AK038357, AK020824, AK171985, AK053153, AK042735, and AK143096. (C) Expan-
sion of the genomic region coveredby the cis-NATAK042735. The214-bp-longexonprobe thatwasdesignedagainst the cis-NATof LEDGF is
indicated by an empty box. Accession numbers of equivalent transcripts in other species: rat – CB576984; human – AV716383, DA171947;
cow –CK778664, BF654277. (D) RT-PCR analysis of RNA frommouse, rat, and human origins performedwith LEDGF/p75 antisense-specific
primers designed to encompass the exon probe (indicated by an open box 4 in panels A and C and an arrow in panel A). Row antisense/RNA
indicates that RT reactionwas carried out with no enzyme supplementation and serves as a control tomonitor genomic contamination in the
samples. (E) Analysis of VEGF-C and LEDGF sense and antisense transcripts by specific RT-PCR in control A549 (−) or stably overexpressing
LEDGF antisense construct (+). For amplification of antisense transcripts, sense-specific primerswere added to reverse transcription,where-
as for the detection of the sense transcripts, antisense primers were added to reverse transcription. Row antisense/RNA is as in panel D. (F)
Relative intensity of the bandswas normalized against GAPDH and is summarized in the bar graph. (G) Immunoblot assay of VEGF-C, LEDGF/
p75, and β-tubulin protein extracted from A549 cells stably transfected with an empty vector (−) or with a construct expressing LEDGF anti-
sense (+). (H and I) H1299 cells were cotransfected with VEGF-C–luciferase reporter and empty vector (pIRES) or vector expressing LEDGF
antisense (pIRES-LEDGFas) that reduces the expression of LEDGF/p75. Cells were then incubated with 0.2 mM H2O2 for 12 hours (H) or
heated to 42°C for 6 hours followed by an additional 6-hour incubation at 37°C (I; mean ± SD, n = 3). (J) Attenuation of pVEGF-Cwt-Luc
reporter activity as a result of knockdown of LEDGF/p75 expression using a specific synthetic siRNA. As a control, a nontarget siRNA was
applied (mean ± SD, n = 3).
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Ectopic Expression of LEDGF Promoted Tumor Angiogenesis
and Lymphangiogenesis and Induced VEGF-C Expression
To evaluate whether enhanced expression of LEDGF/p75 was suffi-
cient for stimulating the expansion of subcutaneous blood and lym-
phatic vessels, subcutaneous angiogenesis and lymphangiogenesis were
assessed by intravital imaging using two tumor models, a dorsal skinfold
window chamber and subcutaneous tumors in the mouse ear. H1299
human lung cancer cells and C6 rat glioma cells, both of which express a
low endogenous level of VEGF-C, were engineered to stably express
DsRed2 fluorescent protein alone (control) or together with LEDGF.
Tumors were established in 8-week-old CD-1 nude female mice (n =
5 per group) by inoculating either a suspension of fluorescent H1299
cells (2 × 106) to the center of a dorsal skinfold window chamber or
C6 cells (3 × 105) to the edge of the mouse ear.
Functional blood vessels were visualized by DLSI (green) [43,44],
whereas the tumor signal was detected by fluorescence microscopy
(red; Figure 5, A–D). A significant increase in functional blood vessel
density was detected in LEDGF-overexpressing H1299 tumors de-
veloped within the dorsal skinfold window chamber as early as 8 days
after tumor cell inoculation (Figure 5, C and D) in comparison to
control tumors (Figure 5, A and B). The tumor blood vasculature in
each group of mice (n = 5) was analyzed using the fractal box count
method, providing the complexity of blood vessel network. A signifi-
cant increase (P = .025) in blood vessels’ complexity was deduced from
the analysis of LEDGF-overexpressing tumors in comparison to control
tumors (Figure 5E).
The lymphatic network was visualized 7 days after inoculation of C6
glioma cells to the mouse ear by intradermal injection of dextran-FITC
(500 kDa; green) in two sites of a mouse ear, whereas the tumor was
detected by fluorescence microscopy (red ) and blood vessels were de-
tected by DLSI (blue; Figure 5, E and F). A pronounced elevation in
lymphatic network complexity was induced by the LEDGF-expressing
tumors, showing increased density in comparison to control tumors
(Figure 5, E and F ). Further fractal box-count analysis of the lymphatic
network revealed that overexpression of LEDGFresults in a significantly
more complex network (Figure 5H ; P = .0194).
The impact of LEDGF/p75 overexpression was evaluated in histo-
logic specimens generated from the previously mentioned tumors at
the end point of each experiment. No significant pathologic differ-
ences were observed by hematoxylin-eosin histologic sections of the
unifocal tumors developed in the dorsal skinfold window chamber in
the presence or absence of LEDGFoverexpression (Figure 6, compare A
Figure 6. LEDGF/p75overexpression in tumorsstimulatesblood and lymphatic vessels’ sproutingand inductionofVEGF-Cexpression.Exvivo
analysis of subcutaneous tumors excised frommice inoculatedwith tumor cells in a dorsal skinfoldwindowchamber (H1299 cells; A, B, E, F, I,
J, M, and N) or in a tip of an ear (C6 cells; C, D, G, H, K, L, O, and P). Histologic sections stained with hematoxylin-eosin. (A and B) H1299
control and LEDGF-overexpressing tumors, respectively. (C andD) C6 control and LEDGF-overexpressing tumors. Scale bar, 200 μm. Immuno-
histochemical staining with anti-CD34 antibody of blood vessels in control H1299 and C6 (E and F, respectively) and LEDGF-overexpressing
tumors (G and H, respectively; scale bar, 100 μm). Immunohistochemical staining of lymphatic endothelial cells using anti–LYVE-1 antibodies
(H1299: control [I] and LEDGF-overexpressing tumors [J];C6: control [K] andLEDGF-overexpressing tumors [L]; scale bar, 100 and50μmin the
insert picture). In situhybridization analysis usingVEGF-C as a probe, indicating that VEGF-Cexpression is induced in tumors initiated fromcells
overexpressing LEDGF (H1299: control [M] and LEDGF overexpression [N]; C6: control [O] and LEDGF overexpression [P]; scale bar, 100 μm).
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with B). In contrast, in the ear tumor model, overexpression of LEDGF
developed multifocal tumors along the entire peripheral side of the
ear (Figure 6, arrows), whereas control cells developed a single tumor
(Figure 6, compareC withD). The effects on the tumor growth pattern
are in accord with the effect of LEDGF on cell invasion and migra-
tion (Figure W2).
Blood vessel density was elevated by LEDGF overexpression in the
two tumor models, as determined through immunohistochemical
staining using a MoAb against CD34 (Figures 6 and W3). However,
the effect of LEDGFon the density of vessels was statistically significant
only for H1299 tumors, in which the baseline vessel density was lower
relatively to the highly angiogenic C6 tumors (Figures 6, G , H , and E ,
F, and W3; 3.97-fold, P = .07; and 3.26-fold, P = .01; increased vessel
count for C6 and H1299, respectively). Conversely, LYVE-1, a lym-
phatic endothelial marker, revealed that overexpression of LEDGF/
p75 significantly increased the density of lymphatic vessels within and
around tumors for both C6 and H1299 tumors (Figures 6, I , J and K ,
L, andW3; 56.39-fold, P = 1.2 × 10−6; and 3.43-fold, P = .02; increased
density of LYVE-1–positive vessels for C6 and H1299, respectively).
In situ hybridization analysis demonstrated enhanced VEGF-C ex-
pression inH1299-LEDGF, as well as in C6-LEDGF tumors (Figure 6,
M ,N andO, P, respectively), which was consistent with the prominent
LEDGF overexpression level. Thus, the in vivo analysis of tumor xeno-
grafts in the two distinct models corroborated the role of LEDGF in
inducing the expression of VEGF-C and regulating angiogenesis and
lymphangiogenesis in tumors.
Discussion
Angiogenesis and lymphangiogenesis provide complementary mech-
anisms for matching tissue requirements for nutrient supply and waste
product clearance. Thus, regulation of both processes should be fine-
tuned to microenvironmental signals. A notable example is the regula-
tion of angiogenesis by the hypoxia-induced expression of VEGF-A,
as mediated by the activity of hypoxia-inducible factor 1 [56]. We re-
port here an analogous molecular pathway modulating lymphangio-
genesis through the stress-regulated expression of VEGF-C mediated
by LEDGF/p75 (Figure W4).
VEGF-C is currently considered to play a central role in the control
of lymphatic endothelial cell biology during embryogenesis [3], tumori-
genesis [57], and metastasis [58]. The study presented here reports the
identification of a novel molecular mechanism for microenviron-
mental regulation of VEGF-C activity. We demonstrated that VEGF-C
expression is controlled in vitro and in vivo by the p75 splice variant of
LEDGF, a novel growth and survival transcriptional activator. VEGF-C
can thus be added to a growing list of stress-related proteins, including
antioxidant protein 2, Hsp27, αB-crystallin, and Hsp90, all of which
are transcriptionally regulated by LEDGF/p75 [29,59].
LEDGF activity is induced by a variety of environmental stress
signals and regulates downstream response pathways by enhancing
expression through binding to a specific STRE and/or HSE consensus
core sequence, located in the promoter region of its target genes. It was
shown here that LEDGF/p75 transactivated VEGF-C transcription by
interacting with specific species-conserved STREs. Disruption of these
conserved STREs significantly attenuated the expression of VEGF-C.
Point mutations introduced within these conserved STREs suppressed
the transcription activity of the VEGF-C gene.
In addition to its role as a survival factor, LEDGF/p75was implicated
in various human diseases including atopic disorders [31], integration
of the human immunodeficiency virus in acquired immunodeficiency
syndrome [60], and cancer. It was shown to be involved in a t(9;11)
(p22;p15) recurrent translocation to form a NUP98-LEDGF fusion
protein in acute and chronic myeloid leukemia [61]. LEDGF was re-
cently found to be associated with MLL and menin, thus placing it
at the center of a pathway in cancer pathogenesis [62]. LEDGF/p75 ex-
pression is elevated in 93% of prostate tumors [32]. It was reported that
αB-crystallin, a target of LEDGF, is expressed in basal-like tumors and
predicted poor survival in breast cancer patients [63].
An additional target of LEDGF, heat shock protein 27 (Hsp27), is
highly expressed in tumors and contributes to tumor progression and
metastasis [26]. Moreover, LEDGF/p75 was shown to be associated
with JPO2, aMyc-binding protein [64]. LEDGF/p75was also reported
to control a caspase-independent lysosomal cell death pathway in cancer
cells [33]. Thus, LEDGF/p75 seems to be implicated in multiple path-
ways affecting cancer progression. It also has an important role during
development, as was evident by the perinatal lethality of LEDGF-
deficient mice [65].
As shown here, VEGF-C expression was induced by LEDGF/p75
overexpression, whereas suppression of cellular LEDGFusing a synthetic
LEDGF antisense construct, attenuated the endogenous VEGF-C
mRNA and polypeptide levels. To evaluate whether elevated expres-
sion of LEDGF/p75 was sufficient for induction of angiogenesis and
lymphangiogenesis, we challenged the subcutaneous vasculature to
H1299 human lung cancer cells and C6 rat glioma cells engineered
to overexpress LEDGF/p75. Both cell lines were found to express low
endogenous level of both VEGF-C and LEDGF/p75, and expression
was augmented by elevated expression of LEDGF/p75. Intravital
microscopy revealed increased density of subcutaneous blood vessels
in the periphery of LEDGF/p75–overexpressing H1299 tumors and
increased density of lymphatic vessels in the periphery of LEDGF/
p75–overexpressing C6 tumors. Quantitative analysis of both vascular
beds was done by semiautomatic determination of the fractal dimen-
sion Df [47–51].
Accordingly, histologic analysis showed that ectopic overexpression of
LEDGF/p75 was sufficient for promoting tumor VEGF-C expression,
angiogenesis, and lymphangiogenesis. Lymphangiogenesis was signifi-
cantly and robustly induced, resulting in increased density of LYVE-1–
positive lymphatic vessels for both C6 and H1299 tumors. Histologic
sections revealed a significantly elevated density of CD34-positive blood
vessels for both tumor types; however, the change was statistically sig-
nificant only for H1299 tumors in which the endogenous density of
blood vessels was low relative to the highly angiogenic C6 tumors.
The observation that subcutaneous LEDGF-overexpressing C6
cells generated multifocal tumors may indicate that these cells inher-
ited both migration and invasion potential, as shown previously for
VEGF-C–overexpressing cells, using this tumor model [8]. As shown
here, LEDGF/p75–induced migration and invasion could be mea-
sured in vitro also for H1299 cells. These tumorigenic properties may
further explain the observed aggressiveness of tumors that express high
LEDGF/p75 levels.
Future studies should evaluate the significance of LEDGF/p75 in
the regulation of expression of VEGF-C in human cancers. The impact
of overexpression of LEDGF/p75 on tumor angiogenesis, lymphangio-
genesis, invasion, and migration suggests that it could affect progression
also for tumors with low propensity to form lymph node metastases.
Moreover, VEGF-C induced by LEDGF/p75 could potentially help
sustain tumor progression in a VEGF-A refractory manner, providing
tumors with a potentialmechanism to escapeVEGF-A–targeted therapy.
The clinical significance of this pathway remains to be evaluated.
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An interesting aspect is the regulation of LEDGF by reactive oxygen
species (ROS) in general and by hydrogen peroxide (H2O2) in particu-
lar. Increased levels of H2O2 were linked to DNA alterations, cell pro-
liferation, apoptosis resistance, metastasis, and angiogenesis in cancer
[66,67]. We reported here that VEGF-C expression is significantly
stimulated in the presence of H2O2 in a LEDGF/p75–dependent
manner. Similarly, hyperthermia the expression of both LEDGF/p75
and VEGF-C. Previously, it was reported that cells subjected to a tran-
sient 4-hour exposure to 42°C followed by a 24-hour recovery showed
suppressed expression of VEGF-A and reduced angiogenesis [68].
Thus, hyperthermia can possibly augment angiogenesis and lymph-
angiogenesis by the elevated expression of LEDGF/p75 and VEGF-C,
whereas resolution of hyperthermia-induced angiogenesis and recov-
ery from hyperthermic stress is associated with the attenuated expres-
sion of VEGF-A.
The regulation of LEDGF expression may help shed light on the
stress response pathways in tumor cells. In silico data supported the
existence of cis-NAT of mouse, human, rat, and cow LEDGFas,
which are transcribed from the opposite strand of the LEDGF locus
and are specific for the p75 variant. Natural antisense RNA are widely
distributed to viruses, prokaryotes, and eukaryotes and are also pre-
dicted to be abundant in mammals, including both human and mouse
[69]. Indeed, computer predictions have estimated that natural anti-
sense genes comprise as much as 20% of the human genome [70]. Anti-
sense RNA may contribute to regulatory activity at various levels, such
as posttranscription, splicing, transport, and genomic imprinting [71].
We demonstrated that the human cis-natural antisense mRNA
of LEDGF was functionally active and was able to regulate in vitro
both basal and stress (H2O2 and heat shock)–induced VEGF-C levels.
Ectopic expression of LEDGFas significantly diminished LEDGF/p75
protein amounts, whereas its effect on RNA level was less prominent.
Thus, we hypothesize that LEDGFas represents a novel posttranscrip-
tional gene regulation layer that specifically controls LEDGF/p75 poly-
peptide levels and LEDGF/p75 functions.
In summary, we report here a novel role for LEDGF/p75 in control-
ling microenvironmental regulation of structural changes in the lym-
phatic vasculature through expression of VEGF-C. Lymphangiogenesis,
induced in response to stress cues, can alleviate edema and help main-
tain tissue homeostasis by augmenting the capacity for fluid clearance
but can also facilitate tumor metastasis. The effect of LEDGF/p75 on
tumor expression of VEGF-C and lymphangiogenesis suggests that
LEDGF/p75 should be evaluated among the multiple potential targets
for cancer therapy.
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Figure W1. VEGF-C expression is induced by elevated culture medium pressure. (A) VEGF-C and LEDGF/p75 mRNA expression was
analyzed by RT-PCR analysis in H1299 human lung cancer cells maintained in elevated column of culture medium (50 ml/1.1 cm) for the
indicated time. (B) Relative intensity of the bands normalized against GAPDH. (C) Luciferase assay carried out with H1299 cells transiently
transfected with pVEGF-Cwt-Luc reporter and cultured either in 3-ml (0.2 cm) or in high 50-ml culture medium (mean ± SD, n = 3).
Figure W2. Overexpression of LEDGF/p75 augments migration and
invasion rate of H1299 lung cancer cell in vitro. (A) Cell migration
assay carried out in vitro with H1299 encoding the p75 variant
of LEDGF (LEDGF) and control cells expressing an empty vector
(Control). (B) Density of cells that had migrated through the filter. (C)
Invasion of H1299 encoding LEDGF (LEDGF) and control cells (Con-
trol) through Matrigel. Cells were plated in transwell invasion cham-
bers coated with Matrigel, and 12 hours later, cells that hadmigrated
through the filter were stained. (D) Density of cells that invaded
through the Matrigel. Three independent experiments were each
carried out with at least triplicates, *P < .01.
Figure W3. Ectopic expression of LEDGF/p75 augments blood and
lymphatic vessels’ quantity in H1299 and C6 tumors. The impact of
LEDGF/p75 overexpression on blood and lymphatic vessels density
was evaluated in the tumors described inFigures 5 and6.Angiogene-
sis and lymphangiogenesis rates were deduced by counting the
number of blood and lymphatic vessels after immunohistochemical
stainingusingeither antibodies againstCD34or LYVE-1, respectively.
Data are presented as mean ± SD for fold induction of LEDGF/p75
over control tumors from at least three different tumors from each
group normalized to the tumor section area (note the log scale of ves-
sel density fold induction; *P < .05).
Figure W4.Microenvironmental control of tumor angiogenesis and lymphangiogenesis by LEDGF/p75. Angiogenesis and lymphangiogenesis
are two complementary processes that play a vital role in physiological and pathologic circumstances. A key regulator of angiogenesis is the
HIF-1 that is activated by hypoxia and oxidative stress. HIF-1 activates the transcription of hypoxia response element–containing genes involved
in diverse aspects of cellular and integrative physiology, including energy metabolism (glycolytic enzymes and glucose transporters), survival
(insulin-like growth factor 2 [IGF-2] and IGF-binding protein [IGFBP] 1,2,3), erythropoiesis (EPO), vasodilation (inducible nitric oxide synthase
[I-NOS] and heme oxygenase 1 [HO-1]), and angiogenesis (VEGF, VEGF receptor fms-related kinase 1 [FLT-1]). In analogy, we show here
that LEDGF is elevated by various stress signals including oxidative stress and hyperthermia. LEDGF confers its activity through binding to
specific promoter elements (STRE and/or HSE) of many stress-related genes known to be involved in survival (heat shock proteins [HSPs],
αB-crystallin) and in antioxidation (antioxidant protein 2 [AOP2]) and activates them. We propose here that LEDGF regulates lymphangio-
genesis by mediating stress-induced expression of VEGF-C.
